Ravinder Wali to Chronic Disease
This is a "connection" page, showing publications Ravinder Wali has written about Chronic Disease.
Connection Strength
0.305
-
Wali RK, Iyengar M, Beck GJ, Chartyan DM, Chonchol M, Lukas MA, Cooper C, Himmelfarb J, Weir MR, Berl T, Henrich WL, Cheung AK. Efficacy and safety of carvedilol in treatment of heart failure with chronic kidney disease: a meta-analysis of randomized trials. Circ Heart Fail. 2011 Jan; 4(1):18-26.
Score: 0.068
-
Wali RK. Aspirin and the prevention of cardiovascular disease in chronic kidney disease: time to move forward? J Am Coll Cardiol. 2010 Sep 14; 56(12):966-8.
Score: 0.067
-
Wali RK, Weir MR. Chronic allograft dysfunction: can we use mammalian target of rapamycin inhibitors to replace calcineurin inhibitors to preserve graft function? Curr Opin Organ Transplant. 2008 Dec; 13(6):614-21.
Score: 0.059
-
Wali RK, Mohanlal V, Ramos E, Blahut S, Drachenberg C, Papadimitriou J, Dinits M, Joshi A, Philosophe B, Foster C, Cangro C, Nogueira J, Cooper M, Bartlett ST, Weir MR. Early withdrawal of calcineurin inhibitors and rescue immunosuppression with sirolimus-based therapy in renal transplant recipients with moderate to severe renal dysfunction. Am J Transplant. 2007 Jun; 7(6):1572-83.
Score: 0.054
-
Wali RK, Henrich WL. Chronic kidney disease: a risk factor for cardiovascular disease. Cardiol Clin. 2005 Aug; 23(3):343-62.
Score: 0.047
-
Weinman EJ, Lakkis J, Akom M, Wali RK, Drachenberg CB, Coleman RA, Wade JB. Expression of NHERF-1, NHERF-2, PDGFR-alpha, and PDGFR-beta in normal human kidneys and in renal transplant rejection. Pathobiology. 2002-2003; 70(6):314-23.
Score: 0.009